Manitoba Health

Vaccine Clinic Resource for Immunizers

Disclaimer: *this Quick Reference is not intended to replace other product specific vaccine references. The document is intended as a quick reference for frequently referred to information. Please refer to the product monograph and vaccine specific resources for all current and complete information.*

Title:	**School Based Clinic (Grade 6 and Grade 8/9) - Quick Reference Guide** ***This guide also provides additional information for those who may have missed the school based clinics and require catch-up immunizations.***
Effective Date:	July 11, 2025
Approver:	Final

School Based Vaccine Resources:

Fact sheets and Product Monographs

www.manitoba.ca/health/publichealth/cdc/div/sip.html

Eligibility Criteria

For the most up to date information on eligibility criteria refer to www.manitoba.ca/health/publichealth/cdc/vaccineeligibility.html

Manitoba Immunization Schedule:

www.manitoba.ca/health/publichealth/cdc/div/schedules.html

Canadian Immunization Guide:

For additional guidance on contraindications, precautions and special populations refer to each vaccine specific section:
www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines.html

Manitoba Health

Hepatitis B (HB) Vaccine

Product	Storage and Handling	Eligibility Criteria	Recommendations for Use
ENGERIX®-B **Hepatitis B vaccine** (recombinant) **Format:** Pre-filled 1.0 mL syringe (single dose) **or** Pre-filled 0.5 mL syringe (single dose) (1 per/box) *RECOMBIVAX HB® had been used routinely in Manitoba in the past and can be interchanged with* ***ENGERIX®-B*** *NACI Recommendation - Monovalent hepatitis B vaccines may be used interchangeably, according to the recommended dosage and schedule.*	**Storage:** Refrigerated 2° to 8°C until expiry date on label. **Do NOT freeze. Protect from light.** **Handling:** Reconstitution NOT required The vaccine should be inspected visually for any foreign particulate matter and/or coloration prior to administration. Before use of ENGERIX-B, the vaccine should be well shaken to resuspend the sediment of fine white particles of adjuvant (aluminum hydroxide) which settles during storage and to obtain a slightly opaque, white suspension. Discard if the content appears otherwise.	• All children born on or after January 1st, 2006 in the grade 6* school-based program that are 11-15** years of age are eligible for the 1.0ml, 2 dose schedule *Children who are 10 years of age for their first dose of HBV in Grade 6 (birthday between Sept and Dec of that year), are eligible for the 1.0 ml, 2 dose schedule. **Children 11 to 15 years of age who have had one or two pediatric doses (0.5mL/dose) will require 3 doses to complete their series. They can complete with the 0.5 ml (10mcg) dose(s), or if necessary, immunizers can finish the 3-dose series with 1.0 mL (20mcg) dose(s) (e.g. vaccine supply available is prefilled 1.0 mL syringe only).	**Regimen:** 2 dose schedule: 0, 6 months **Dosage:** 1.0 ml (20 mcg) **Route:** IM **Interval:** Minimum interval is 6 months (24 weeks) *Note re: PHIMs forecaster:* • *If both 1.0ml doses are not received before the age of 16, the forecast will revert to a three-dose schedule.* • *If the 2nd dose is less than the minimum interval it will forecast for 3 doses* • *If the dosage of the Hep B product is not specified or if the dosage is < 1 ml it will forecast a 3 dose 0.5 ml/dose schedule*
		• Children/adolescents 16-18 years of age	**Regimen:** 3 dose schedule: 0, 1, 6 months **Dosage:** 0.5 ml (10 mcg) **Route:** IM **Interval:** Although a schedule of months 0, 1 and at least 2 is authorized, the preferred schedule is months 0, 1 and 6
		• Individuals of any age who meet the high-risk criteria may be eligible for 3 or 4 doses of hepatitis B vaccine. Refer to Manitoba Health Eligibility Criteria and Canadian Immunization Guide for eligibility and dosage requirements	

Product is latex and preservative/thimerosal free
Potential Allergens: Yeast protein ***Other Ingredients:*** *aluminum hydroxide (adjuvant), disodium phosphate dehydrate, sodium dihydrogen, phosphate dehydrate*, sodium chloride, water for injection

Pregnancy and lactation: Can be used safely during pregnancy and breastfeeding

Manitoba Health

Human Papillomavirus 9 Valent (HPV-9) vaccine			
Product	**Storage and Handling**	**Eligibility Criteria**	**Recommendations for Use**
Gardasil®9 Human Papillomavirus 9-valent Vaccine, Recombinant HPV (6, 11,16,18,31,33, 45,52, and 58) L1 protein **Format:** Pre-filled 0.5 mL syringe (10 per/box) Whenever possible, the same HPV vaccine should be used to complete a vaccine series. However, if previously immunized with dose(s) of Gardasil®4 then complete the series with Gardasil®9 (CIG).	**Storage:** Refrigerated 2° to 8°C until expiry date on label. **Do NOT freeze. Protect from light.** **Handling:** Reconstitution NOT required Gardasil®9 should be administered as soon as possible after being removed from refrigeration. Shake well before use. Thorough agitation immediately before administration is necessary to maintain suspension of the vaccine. Discard the product if it is frozen, particulates are present, or if it appears discolored.	• Individuals (immunocompetent) 9 to 14 years of age are eligible to receive the HPV vaccine, routinely provided as part of the grade 6 school-based immunization program.	**Regimen:** 2 dose schedule: 0, 6 months **Dosage:** 0.5 mL **Route:** IM **Interval:** Minimum interval between the first and second dose of vaccine is 6 months (24 weeks). If a second dose is administered earlier than 6 months, a third dose should be given at least 6 months (24 weeks) after the first dose.
		• Individuals (immunocompetent) 15 years* of age and older if born on or after 1997 (females) OR born on or after 2002 (males) **For those who missed the school-based program, a 3-dose schedule is recommended, unless the first dose of vaccine was administered before the age of 15 yrs.*	**Regimen:** 3 dose schedule: 0, 2, 6 months **Dosage:** 0.5 mL **Route:** IM **Interval:** The minimum interval between the first and second doses of vaccine is 4 weeks (1 month), the minimum interval between the second and third doses of vaccine is 12 weeks (3 months), and the minimum interval between the first and last doses is 24 weeks (6 months).
		• Individuals 9 years and older who meet the high-risk criteria may be eligible for 3 doses of HPV vaccine. Refer to Manitoba Health Eligibility Criteria and Canadian Immunization Guide for eligibility and dosage requirements	
Product is latex and preservative/thimerosal free **Potential Allergens:** Yeast protein, polysorbate 80 (may also be found in bowel preparation, PEG, laxatives, corn syrup, cosmetics, etc.) ***Other Ingredients:*** aluminum (as amorphous aluminum hydroxyphosphate sulfate adjuvant), L-histidine, sodium borate, sodium chloride, water for injection **Pregnancy and lactation:** HPV vaccines can be offered in pregnancy. Current evidence suggests that there is no increased risk of adverse pregnancy or fetal outcomes linked to HPV vaccination during pregnancy. Limited data on breastfeeding, but not contraindicated.			

Manitoba Health

Meningococcal Quadrivalent Conjugate (Men-C-ACYW) Vaccine

Product	Storage and Handling	Eligibility Criteria	Recommendations for Use
Nimenrix® Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine **Format:** Single dose vial of sterile lyophilized white powder or cake; diluent presented in a pre-filled syringe (0.5 ml) Single or 10/box vial	**Storage:** Refrigerated 2°to 8°C until expiry date on label. **Do NOT freeze. Protect from light.** **Handling:** Reconstitution required Add the entire contents of the pre-filled syringe of diluent to the vial containing the powder. The reconstituted vaccine is a clear, colourless solution. After reconstitution, the vaccine should be used promptly.	• Individuals born on or after January 1, 2008 are eligible to receive a dose at ≥10 years of age, routinely offered in Grade 6, regardless of Men-C-C or Men-C-ACYW immunization history • Individuals born between 1995 and 2007 are eligible to receive a dose if they have no previous history of receiving a Men-C-C vaccine	**Regimen:** 1 dose* **Dosage:** 0.5 mL **Route:** IM **Interval:** **Those with certain high-risk medical conditions may require additional doses - see Manitoba Health eligibility criteria for complete list and refer to the Canadian Immunization guide for dose requirements and intervals*
Product is latex and preservative/thimerosal free. **Potential Allergens:** Tetanus toxoid carrier protein ***Other Ingredients:*** Sucrose, Trometamol, Sodium chloride, water for injection **Pregnancy and lactation:** Conjugate quadrivalent meningococcal vaccine should be considered in pregnancy. Limited data on breastfeeding, but not contraindicated.			

Tetanus, Diphtheria, acellular Pertussis (Tdap) Vaccine

Product	Storage and Handling	Eligibility Criteria	Recommendations for Use
Boostrix® Combined diphtheria, tetanus, acellular pertussis (adsorbed) vaccine for booster vaccination **Format:** Pre-filled 0.5 mL syringe 10 per/box	**Storage:** Refrigerated 2° to 8°C until expiry date on label. **Do not freeze. Protect from light.** **Handling:** Reconstitution NOT required Shake vaccine well to obtain a homogeneous turbid white liquid.	• Individuals 13 to 15 years of age (Grade 8 or 9 school-based program). *Any dose after the age of 10 can be counted as an adolescent booster.*	**Regimen:** 1 dose* **Dosage:** 0.5 mL **Route:** IM **Interval:** There is no minimum interval between the Td and Tdap vaccine when Tdap is being given for pertussis protection (NACI).
Product is latex and preservative/thimerosal free **Potential Allergens:** polysorbate 80 (may also be found in bowel preparation, PEG, laxatives, corn syrup, cosmetics, etc.) ***Other Ingredients:*** Formaldehyde, glycerin, sodium chloride, water for injection, aluminum (as aluminum salts) **Pregnancy and lactation:** Can be used safely during pregnancy and breastfeeding			

Manitoba Health

Tetanus, Diphtheria, acellular Pertussis and Polio (Tdap-IPV) Vaccine			
Product	**Storage and Handling**	**Eligibility Criteria**	**Recommendations for Use**
Boostrix-Polio® Combined diphtheria, tetanus, acellular pertussis (adsorbed) and inactivated poliomyelitis vaccine for booster vaccination **Format:** Pre-filled 0.5 mL syringe 10 per/box	**Storage:** Refrigerated 2° to 8°C until expiry date on label. **Do not freeze. Protect from light.** **Handling:** Reconstitution NOT required Shake vaccine well to obtain a homogeneous turbid white liquid.	• Individuals 7-17 years of age that also require the polio antigen (IPV)	**Regimen:** 1 dose* *Some students may be forecasted for additional catch-up doses. **Dosage:** 0.5 mL **Route:** IM **Interval:** Refer to the following table for dose requirements and intervals: https://www.manitoba.ca/health/publichealth/cdc/div/not.html#more
Product is latex and preservative/thimerosal free **Potential Allergens:** neomycin, polymycin B sulphate ***Other Ingredients:*** Aluminum (as aluminum salts), formaldehyde, medium 199, sodium chloride, water for injection medium 199, sodium chloride, water for injection. **Pregnancy and lactation:** Can be used during pregnancy and breastfeeding			